D L Citrin
Overview
Explore the profile of D L Citrin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
269
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Obasaju C, Manola J, Hudes G, Khandekar J, Citrin D, Carbone P, et al.
Am J Clin Oncol
. 2001 Apr;
24(2):150-4.
PMID: 11319290
Menogaril is a semisynthetic anthracycline that is less cardiotoxic than doxorubicin in a preclinical model. We conducted a phase II trial to determine the activity of menogaril in hormone-refractory prostate...
2.
Haas N, Manola J, Hudes G, Citrin D, Kies M, Davis T
Am J Clin Oncol
. 2001 Feb;
23(6):589-92.
PMID: 11202803
Twenty-nine patients with progressive hormone-refractory metastatic adenocarcinoma of the prostate were treated with daily estramustine phosphate at 10 mg/kg, and I.V. doxorubicin 50 mg/m2 every 3 weeks. Twenty-six patients were...
3.
Decker R, Elson P, Hogan T, Citrin D, WESTRING D, Banerjee T, et al.
Surgery
. 1991 Dec;
110(6):1006-13.
PMID: 1745969
From November 1979 to July 1986, 52 patients (27 women and 25 men; median age 52 years) with advanced adrenocortical carcinoma entered a prospective, nonrandomized study evaluating moderate-dose mitotane and...
4.
Citrin D, Resnick M, Guinan P, Scott M, Gau T, Kennealey G
Prostate
. 1991 Jan;
18(2):139-46.
PMID: 1826048
This open, prospective study was conducted to compare ZOLADEX (goserelin acetate implant) and diethylstilbestrol (DES) in the treatment of stage D2 prostate cancer. Sixty-seven patients were allocated to receive 3.6...
5.
Ahmann F, Citrin D, deHaan H, Guinan P, Jordan V, Kreis W, et al.
J Clin Oncol
. 1987 Jun;
5(6):912-7.
PMID: 2953870
Zoladex, a sustained-release luteinizing hormone--releasing hormone (LHRH) analogue administered by subcutaneous injection every 28 days, was evaluated at three dose levels in 46 men with untreated advanced prostate cancer. All...
6.
Schiller J, Rasmussen P, Benson 3rd A, Witte R, Bockman R, Harvey H, et al.
Arch Intern Med
. 1987 May;
147(5):963-6.
PMID: 3107487
Normocalcemic patients with cancer who had been successfully treated for an episode of hypercalcemia were enrolled in a randomized, multisite, double-blind, placebo-controlled trial designed to determine the efficacy of maintenance...
7.
Witte R, Koeller J, Davis T, Benson 3rd A, Durie B, Lipton A, et al.
Arch Intern Med
. 1987 May;
147(5):937-9.
PMID: 2953318
Malignancy-associated hypercalcemia is a common and recalcitrant problem. Current modes of therapy are often ineffective or prohibitively toxic. Clodronate disodium is a diphosphonate capable of inhibiting bone resorption resulting in...
8.
Citrin D, Wallemark C, Nadler R, Geiger C, Tuttle K, Kaplan E, et al.
Cancer
. 1986 Nov;
58(10):2208-13.
PMID: 3756769
A patient with metastatic prostate cancer is described where treatment with Adriamycin (doxorubicin) and estramustine produced severe hypophosphatemia (serum phosphate level, 1.2 mg/dl), which was reversible when treatment was discontinued....
9.
Citrin D, Kies M, Wallemark C, Khandekar J, Kaplan E, Camacho F, et al.
Cancer
. 1985 Aug;
56(3):457-60.
PMID: 4005808
Twenty-five patients with metastatic prostate cancer resistant to primary hormone therapy, received high-dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES-P) in a Phase II study using established response criteria. Objective...
10.
Citrin D, Elson P, DeWys W
Cancer
. 1984 Jul;
54(1):13-7.
PMID: 6372984
Evaluation of response to systemic therapy in metastatic prostate cancer is often difficult because of the infrequency of nonbony indicator lesions. The authors previously described a set of response criteria...